Inventor
HERSEL ULRICH
DE43 patents
⚠️ This page may combine multiple inventors who share the name “HERSEL ULRICH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ASCENDIS PHARMA GROWTH DISORDERS AS
12 patentsUS10835578B2Nov 17, 2020
CNP prodrugs with large carrier moieties
ASCENDIS PHARMA GROWTH DISORDERS AS21 citations93
US11389511B2Jul 19, 2022
Controlled-release CNP agonists with reduced side-effects
ASCENDIS PHARMA GROWTH DISORDERS AS7 citations85
US11413351B2Aug 16, 2022
CNP prodrugs with carrier attachment at the ring moiety
ASCENDIS PHARMA GROWTH DISORDERS AS7 citations84
US11154593B2Oct 26, 2021
CNP prodrugs with large carrier moieties
ASCENDIS PHARMA GROWTH DISORDERS AS13 citations84
US11389510B2Jul 19, 2022
Controlled-release CNP agonists with low initial NPR-B activity
ASCENDIS PHARMA GROWTH DISORDERS AS5 citations83
US11224661B2Jan 18, 2022
Controlled-release CNP agonists with increased NEP stability
ASCENDIS PHARMA GROWTH DISORDERS AS7 citations80
US12083182B2Sep 10, 2024
Controlled-release CNP agonists with increased NEP stability
ASCENDIS PHARMA GROWTH DISORDERS AS3 citations74
US12156917B2Dec 3, 2024
CNP prodrugs with carrier attachment at the ring moiety
ASCENDIS PHARMA GROWTH DISORDERS AS2 citations73
US11311604B2Apr 26, 2022
Controlled-release CNP agonists with low NPR-C binding
ASCENDIS PHARMA GROWTH DISORDERS AS6 citations72
US12239689B2Mar 4, 2025
Controlled-release CNP agonists with low initial NPR-B activity
ASCENDIS PHARMA GROWTH DISORDERS AS1 citations64
US12544428B2Feb 10, 2026
Controlled-release CNP agonists with reduced side-effects
ASCENDIS PHARMA GROWTH DISORDERS AS0 citations62
US12377133B2Aug 5, 2025
Dry pharmaceutical formulations of CNP conjugates
ASCENDIS PHARMA GROWTH DISORDERS AS0 citations48
ASCENDIS PHARMA AS
7 patentsUS7968085B2Jun 28, 2011
Hydrogel formulations
ASCENDIS PHARMA AS37 citations96
US7879588B2Feb 1, 2011
Protein-proteophore complexes
ASCENDIS PHARMA AS19 citations92
US10980860B2Apr 20, 2021
Diagnosis, prevention and treatment of diseases of the joint
ASCENDIS PHARMA AS11 citations83
US9278139B2Mar 8, 2016
Sterilization of biodegradable hydrogels
ASCENDIS PHARMA AS7 citations83
US10029015B2Jul 24, 2018
Hydrogel formulations
ASCENDIS PHARMA AS2 citations73
US9913912B2Mar 13, 2018
Carrier-linked prostanoid prodrugs
ASCENDIS PHARMA AS2 citations72
US11116849B2Sep 14, 2021
Hydrogel-linked prodrugs releasing tagged drugs
ASCENDIS PHARMA AS0 citations48
RAU HARALD
5 patentsUS9173953B2Nov 3, 2015
Prodrugs containing an aromatic amine connected by an amido bond to a linker
RAU HARALD22 citations89
US9272048B2Mar 1, 2016
PEGylated recombinant human growth hormone compounds
RAU HARALD15 citations87
US8986609B2Mar 24, 2015
Sterilization of biodegradable hydrogels
RAU HARALD6 citations82
US11559482B2Jan 24, 2023
Biodegradable polyethylene glycol based water-insoluble hydrogels
RAU HARALD0 citations50
US9138462B2Sep 22, 2015
Prodrugs comprising an insulin linker conjugate
RAU HARALD1 citations49
HERSEL ULRICH
4 patentsUS9056126B2Jun 16, 2015
Hydrogel formulations
HERSEL ULRICH59 citations96
US9561287B2Feb 7, 2017
Carrier-linked treprostinil prodrugs
HERSEL ULRICH3 citations71
US10729778B2Aug 4, 2020
Carrier-linked treprostinil prodrugs
HERSEL ULRICH1 citations60
US9353170B2May 31, 2016
Long-acting transient polymer conjugates of exendin
HERSEL ULRICH0 citations51